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A enzima purina nucleosídeo fosforilase do parasita Schistosoma mansoni (SmPNP) é um 
alvo molecular atrativo para o desenvolvimento de candidatos a novos fármacos para o tratamento 
da esquistossomose, doença tropical negligenciada que afeta mais de 200 milhões de pessoas 
em todo mundo. No presente trabalho, estudos de cinética enzimática foram conduzidos para 
a determinação da potência e do mecanismo de inibição de uma série de inibidores da enzima 
SmPNP. Além das investigações bioquímicas, estudos cristalográficos e de modelagem molecular 
revelaram importantes bases moleculares para a afinidade de ligação frente à enzima alvo, levando 
ao desenvolvimento de relações entre a estrutura e atividade (SAR).
The enzyme purine nucleoside phosphorylase from Schistosoma mansoni (SmPNP) is an 
attractive molecular target for the development of novel drugs against schistosomiasis, a neglected 
tropical disease that affects about 200 million people worldwide. In the present work, enzyme 
kinetic studies were carried out in order to determine the potency and mechanism of inhibition of 
a series of SmPNP inhibitors. In addition to the biochemical investigations, crystallographic and 
molecular modeling studies revealed important molecular features for binding affinity towards the 
target enzyme, leading to the development of structure-activity relationships (SAR).
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Introduction
Neglected tropical diseases are responsible for millions 
of deaths and disabilities every year. Schistosomiasis is a 
major cause of illness, morbidity and death worldwide. 
Currently, there are about 200 million people infected, 
with more than 650 million living in endemic areas.1 
Praziquantel is the only effective drug available for the 
treatment of schistosomiasis, however, less than 20% of 
those in need currently receive the drug. Additionally, 
praziquantel has been in use for more than 20 years and 
significant resistance to the chemotherapy has emerged.2 
Therefore, this scenario highlights the urgent need for the 
development of new drugs to treat the disease.2,3
Enzymes are attractive biological targets for small-
molecule drug discovery.4,5 Purine nucleoside phosphorylase 
(PNP, EC 2.4.2.1) is a key enzyme in the purine salvage 
pathway which has been primarily studied as a target 
for the treatment of T-cell proliferative diseases, such 
as T-cell leukemias or lymphomas, organ transplant 
rejection, rheumatoid arthritis, psoriasis, and some other 
autoimmune diseases.6,7 In fact, two inhibitors discovered 
at BioCryst Pharmaceuticals are currently undergoing 
clinical trials: (i) BCX1777 (forodesine) for the treatment 
of cutaneous T-cell lymphoma, chronic lymphocytic 
leukemia and acute lymphoblastic leukemia; and 
(ii) BCX4208 for the treatment of gout.8 More recently, it 
has been suggested that PNP inhibitors could also be used 
for the therapy of parasitic tropical diseases, such as malaria 
and schistosomiasis.9-14 The parasite Schistosoma mansoni, 
one of the etiologic agents of human schistosomiasis, lacks 
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the de novo pathway for purine biosynthesis and depends 
entirely on the salvage pathway for its purine requirements 
for synthesis of RNA and DNA.7,11,13 Taking into account 
that PNP from S. mansoni (SmPNP) is an important 
component of the purine salvage pathway and has been 
identified as an attractive drug target, the use of selective 
inhibitors can cause purine starvation, leading to death of 
the parasite.7,13,14
In the present work, we have evaluated a series of 
guanine derivatives against SmPNP in order to determine 
their in vitro potency, affinity and mechanism of inhibition. 
In addition, crystallographic and molecular modeling 
studies were performed to identify the interaction profile of 
the inhibitors, as well as key structural elements responsible 
for the experimental properties.
Experimental
SmPNP, data set and biochemical assays
SmPNP was expressed and purified as described 
previously.9,11 Xanthine oxidase was of the best grade 
available from Sigma Aldrich and was used without further 
purification. All other reagents and solvents were obtained 
commercially from Sigma Aldrich and were of the highest 
purity available. The data set of inhibitors (1-20, Table 1) 
employed in this work, consisting of a series of guanine, 
9-substituted-guanine, 9-substituted-9-deazaguanine 
and 8,9-disubstituted-9-deazaguanine derivatives, were 
synthesized by scientists at BioCryst Pharmaceuticals 
Inc. and are the gift of that organization. Kinetic 
measurements were carried out spectrophotometrically 
with the aid of a Cary100 UV-Vis spectrophotometer, 
using a standard coupled assay as previously described.13-16 
The reaction mixture contained 5 nmol L-1 SmPNP (as the 
monomer), 50 mmol L-1 phosphate buffer (KPO4, pH 7.4), 
10 μmol L-1 inosine, and xanthine oxidase 40 milliunits 
mL-1. Uric acid formation was monitored at 293 nm, in 
triplicate at 25 oC (extinction coefficient for uric acid, 
e293 = 12.9 L mmol-1 cm-1).17 The percentage of inhibition 
was calculated according to the following equation:
% of Inhibition = 100 × (1 - Vi / V0)
where, Vi and V0 are the initial velocities (enzyme 
activities) determined in the presence and in the absence 
of inhibitor, respectively. Compound 3, a known SmPNP 
inhibitor, was used as a positive control for enzyme 
inhibition.13 Values of IC50 (concentration of compound 
required for 50% inhibition of SmPNP) for the whole 
series of inhibitors were independently determined by 
making rate measurements for at least six inhibitor 
concentrations. The type of inhibition and Ki (inhibitor 
constant) values were determined for a subset of potent 
inhibitors under the same experimental conditions for 
three different inhibitor concentrations at five varying 
substrate concentrations (5.0, 7.5, 10, 15 and 20 μmol L-1). 
All kinetic parameters were determined from the collected 
data by nonlinear regression employing the SigmaPlot 
enzyme kinetics module. The values represent means of 
at least three individual experiments. Values of IC50 for 
inhibitors 3, 7, 13, 18 and 20 measured at 10 mmol L-1 
inosine are in good agreement with those previously 
described,13,14 whereas comparable values are not available 
for the other inhibitors of the data set.
Molecular modeling studies
The analyses, calculations and visualizations were 
performed using the programs SYBYL 8.0 (Tripos Inc., 
St. Louis, USA) and Pymol 0.99 (DeLano Scientific, 
Palo Alto, USA). Molecular docking and scoring 
protocols, as implemented in FlexX (BioSolveIT 
GmbH, Sankt Augustin, Germany) and GOLD 4.12 
(Cambridge Crystallographic Data Centre, Cambridge, 
U.K.), were employed to search for reasonable binding 
poses of the ligands within the SmPNP binding pocket. 
The 3D structures of all SmPNP inhibitors used in the 
modeling studies were constructed using CONCORD 
and standard geometric parameters of the molecular 
modeling software package SYBYL 8.0 running on Red 
Hat Enterprise Linux workstations. Although GOLD 
assigns atoms potential according to a pre-established 
internal function, all 3D structures were energetically 
minimized through atom-centered partial charge AM1-
ESP calculations as implemented in MOPAC 6.0 before 
docking runs. This strategy aimed at avoiding possible 
bond length or bond angles distortions present in any 
molecule. The X-ray crystallographic coordinates for 
SmPNP in complex with acetate used in the docking 
protocols were retrieved from the PDB databank (PDB 
ID 1TD1, 1.90 Å resolution). Then, ligands and water 
molecules were discarded and the hydrogen atoms 
were added in standard geometry using the Biopolymer 
module as implemented in SYBYL 8.0. Histidine, 
glutamine, and asparagine residues in the binding site 
were manually checked for possible flipped orientation, 
protonation, and tautomeric states with Pymol 0.99 
side-chain wizard script. Considering that the kinetic 
assays were carried out in pH 7.4 in this work, Glu203 
side-chain was considered as fully ionized in all docking 
runs. The search space sampled in docking runs consists 
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of all amino acid residues within a sphere radius of 
6.5 Å (FlexX) or 10.0 Å (GOLD) centered on the oxygen 
atom of Tyr202. Default parameters were employed to 
generate the poses, which were then ranked by FlexX 
and GOLDSCORE scoring functions. Next, the best 
ranked conformation of each ligand was submitted to 
the web-based interface DrugScore ONLINE to rescore 
the proposed binding modes.18 Only poses that rank well 
in both function and that were consistent with kinetic 
studies were considered further.
Crystallization and soaking of SmPNP
The highly purified SmPNP enzyme was crystallized as 
previously described.11-13 Next, crystals grown at 4 °C in 
20% PEG 1500, 15 mmol L-1 sodium acetate buffer (pH 4.9 
or 5.0) and 20% glycerol (buffer A) were soaked for 48-
96 h in solutions containing 10 mmol L-1 of compound 7 
(Table 1), dissolved in 1:9 DMSO/buffer A.
X-ray data collection and structure refinement
X-ray diffraction data were collected at cryogenic 
temperatures (100 K ) at W01B-MX-2 beamline, equipped 
with a Marmosaic 225 CCD scanner, of the LNLS (National 
Laboratory of Synchrotron Light, in Campinas - Brazil). 
The crystals of SmPNP in complex with compound 7 
(SmPNP-7) diffracted up to 2.30 Å. The data were indexed 
and integrated using the program MOSFLM and scaled 
using the program SCALA from the CCP4 suite.19-22 
Next, the starting phases were determined by molecular 
replacement using SmPNP in complex with acetate 
(PDB ID 1TD1) as the search model, as available in the 
program Molrep.21 The model refinement was carried out 
with Refmac22 and PHENIX23 using sa-weighted 2Fo-Fc 
and Fo-Fc electron density maps. The compounds were 
automatically placed in the electron density using the “Find 
Ligand” routine of Coot.24 Additional manual building 
and placement of water molecules were performed with 
the Coot and PHENIX software. During all steps of the 
refinement, 5% of the data were used to calculate the free 
R-factor25 and thus avoid overfitting. All final models 
were validated using PROCHECK.26 The coordinates and 
structures factors of SmPNP-7 complex are deposited in 
the PDB under ID 3DJF.
Results and Discussion
Considering the key role of PNP in the purine salvage 
pathway of the S. mansoni parasite, this enzyme has been 
selected as a potential target for the chemotherapeutic 
treatment of schistosomiasis. Despite the significant 
amount of structure-activity relationship (SAR) studies 
available for inhibitors of the mammalian PNPs,15,27 similar 
investigations for SmPNP remain outstanding, and would 
be essentially important for the design of new inhibitors. 
The difference of about 6-fold in the KM (Michaelis-
Menten constant) values between human and parasite PNPs 
(human PNP = 41 mmol L-1, SmPNP = 6.4 mmol L-1) for the 
natural substrate (inosine) indicates that binding affinity 
depends on specific molecular interactions between small-
molecule ligand and protein. As a matter of fact, the first 
SmPNP inhibitors were only recently characterized in the 
literature.13,14 In an effort to expand our studies, enzyme 
kinetic, crystallographic and molecular modeling studies 
were carried out to investigate the fundamental chemical 
and structural requirements involved in the inhibition of 
the catalytic activity of SmPNP by a series of guanine 
derivatives. In this context, a series of twenty compounds 
(Table 1) was experimentally evaluated to determine their 
in vitro potency (IC50) and to provide new SAR information.
As can be seen, the two guanine derivatives of 
the data set (compounds 1 and 2) showed moderate 
inhibitory potency against SmPNP (IC50 values of 39 and 
23 μM, respectively). These results contrast with that of 
compound 3 (IC50 = 1.35 μM), a 9-benzyl-9-deazaguanine 
derivative, which is approximately 30-fold more potent than 
the structurally related guanine analog 2. This confirms 
previous studies showing that 9-deazaguanine analogs are 
more potent than the corresponding guanine analogs.6,28,29 
A hypoxanthine analog of the data set (compound 4, 
IC50 = 17 μM), which is structurally related to compounds 
2 and 3, is 12-fold less potent than compound 3, and about 
2-fold more potent than the guanine analog 2. These results 
highlight the importance of the 9-deazaguanine scaffold 
in the development of selective inhibitors of SmPNP, 
indicating that stereochemical features in the ribose binding 
site might play a pivotal role in SmPNP inhibition.
In order to extend our SAR studies, we have evaluated 
some 9-deazaguanines (5-20) possessing a variety of 
substituents in the 9-position. On the basis of structure 
3, we investigated the bioisosteric replacement of the 
methylene group (benzyl group) at position 9 of the purine 
scaffold with an oxygen atom, leading to compound 5. 
However, this structural modification led a 3-fold decrease 
in potency. The substitution of the hydrogen at position 
8 of the purine ring with a methyl group afforded a very 
weak inhibitor of SmPNP (compound 6, IC50 = 200 μM). 
On the other hand, the presence of heteroaromatic 
moieties at position 9 of the purine ring (7 and 8) in place 
of the traditional phenyl group improved potency against 
SmPNP, with IC50 values in the nanomolar range (820 
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Table 1. Inhibitory potency of a series of SmPNP inhibitors
Compound Structure IC50SmPNP / (μM) Compound Structure IC50SmPNP / (μM)
1 HN
N NH
N
O
H2N
NH2 23 ± 2.0 2
HN
N N
N
O
H2N
39 ± 2.6
3
HN
N
H
N
O
H2N
1.35 ± 0.09 4
HN
N
H
N
O
17 ± 1.2
5
HN
N
H
N
O
O
H2N
4.5 ± 0.4 6
HN
N
H
N
O
H2N
CH3 200 ± 22
7
HN
N
H
N
N
O
H2N
0.82 ± 0.05 8
HN
N
H
N
O
H2N
S
0.77 ± 0.08
9
HN
N
H
N
O
H2N S
171 ± 12 10
HN
N
H
N
O
H2N
HO 2.1 ± 0.3
11
HN
N
H
N
O
H2N
Cl 0.87 ± 0.06 12
HN
N
H
N
O
H2N
OH 0.79 ± 0.06
13
HN
N
H
N
O
H2N
Cl 0.51 ± 0.03 14
HN
N
H
N
O
H2N
22 ± 1.8
15
HN
N
H
N
O
H2N
28 ± 2.1 16
HN
N
H
N
O
H2N
NH2 6.4 ± 0.7
17
HN
N
H
N
O
H2N S
12 ± 0.8 18
HN
N
H
N
O
H2N 0.145 ± 0.01
19
HN
N
H
N
O
H2N 0.1 ± 0.01 20
HN
N
H
N
O
H2N
O
0.5 ± 0.08
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and 770 nM, respectively). Our SAR data show that the 
replacement of aromatic (phenyl, pyridine, thiophene) 
to non-aromatic moieties led to new compounds with 
decreased inhibitory potency (14, IC50 = 22 μM; 15, 
IC50 = 28 μM; 16, IC50 = 6.4 μM; and 17, IC50 = 12 μM) 
when compared with those of compounds 7 and 8. The 
substitution on the phenyl group of compound 3 was 
also considered, employing a series of 9-deazaguanines 
having the phenyl group substituted by hydrophilic (10, 
IC50 = 2.1 μM and 12, IC50 = 0.79 μM) and hydrophobic 
(11, IC50 = 0.87 μM and 13, IC50 = 0.51 μM) substituents. 
As can be seen in Table 1, the presence of the ortho- or 
meta-chlorine (11 or 13) or meta-hydroxyl (12) led to 
a slight increase in potency, which was not observed 
for compound 10 (IC50 = 2.1 μM). On the other hand, 
substituents in the para position of the phenyl ring led 
to the most potent inhibitors of this series, compounds 
18 (IC50 = 0.14 μM) and 19 (IC50 = 0.10 μM), suggesting 
that bulkier hydrophobic groups would be important for 
biological activity. The other para-substituted inhibitor 
of the series also confirms this tendency (compound 20, 
IC50 = 0.5 μM).
Although the SAR information gathered from this series 
is valuable and revealed several structural aspects related 
to the inhibitory potency, the underlying explanation for 
these results would require more in-depth investigation. 
Two things are especially important. First, the evaluation 
of the mechanism of SmPNP inhibition associated to the 
determination of the affinity of the inhibitors. Second, the 
structural analysis of the binding mode of the inhibitors into 
the SmPNP active site. In order to explore the mechanism 
of inhibition in more detail, Ki values and the type of 
inhibition with respect to the physiological substrate were 
determined employing a subset of inhibitors as shown 
in Table 2 and Figures 1 and 2. The Lineweaver-Burk 
double-reciprocal plots show the intercepts of the lines 
Figure 1. Competitive inhibitory profile of the SmPNP inhibitors 7 (A), 13 (B), 18 (C) and 19 (D). Kinetic data was collected in the presence of increasing 
concentrations of inhibitor. Panel A 0.8 mmol L-1 (), 1.6 mmol L-1 (q), 3.0 mmol L-1 (r). Panel B 0.8 mmol L-1 (), 1.6 mmol L-1 (q), 3.0 mmol L-1 (r). 
Panel C 150 nmol L-1 (), 300 nmol L-1 (q) and 600 nmol L-1 (r). Panel D 200 nmol L-1 (), 400 nmol L-1 (q) and 800 nmol L-1 (r). In all panels the 
absence of inhibitor is depicted by ().
Table 2. Ki values for a subset of potent SmPNP inhibitors
Compound Ki / (μM) IC50 / Ki 
7 0.451 1.8
13 0.120 4.2
18 0.038 3.9
19 0.071 1.4
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(obtained at three different inhibitor concentrations) 
converging at the y-axis (1/Vmax), whereas the slope 
(KM/Vmax) and the x-axis intercepts (-1/KM) vary with 
inhibitor concentration (Figure 1). Consequently, the Vmax 
values remain constant, whereas the apparent values of KM 
(KMapp, defined as KM(1 + [I]/Ki)) increase with increasing 
inhibitor concentrations. This behavior is consistent with 
a mutually exclusive binding mode between inhibitor and 
substrate, thus indicating that the inhibition of SmPNP was 
found to be competitive for the inhibitors 7, 13, 18 and 19. 
A similar behavior was observed for the other compounds 
of the data set under the same experimental conditions 
(results not shown). 
The determination of the inhibitor constant Ki is 
particularly relevant in the present case, since the IC50 
values were obtained at only one concentration of substrate. 
For competitive inhibitors, IC50 values increase as the 
concentration of the substrate increases. As shown in 
Figure 2, the intersection on the x-axis of the graphs of 
KMapp/Vmaxapp versus inhibitor concentration indicates – Ki. 
The Ki values are collected in Table 2.
The data of Table 2 show that the values of IC50/Ki vary 
from 1.4 to 4.2, which supports the competitive mechanism 
of inhibition. Despite the strong evidences that all of 
9-deazaguanine inhibitors bind to the active site of the 
enzyme, the kinetic data does not provide insights into the 
binding profile of the inhibitors (in the substrate pocket of 
SmPNP). Therefore, crystallization and X-ray studies were 
carried out to complement the kinetic findings. Extensive 
soaking experiments afforded the crystallographic structure 
of SmPNP in complex with the nanomolar inhibitor 7 
(SmPNP-7) at 2.3 Å (Figure 3 and Table 3).
As expected, the purine moiety shows a conserved 
H-bonding network to Glu203 and Asn245, in agreement 
with previous studies for the bovine and human PNPs.27-29 
As can be seen in Figure 3, an extra H-bonding to a 
crystallographic water is found, although this feature 
could be also present in other 6-oxo purine inhibitors with 
moderate potency, such as compound 14 (IC50 = 22 μM). 
As a consequence, the relative high potency of compound 
7 (IC50 = 0.82 μM) might be a result of a more complex 
binding network that incorporates particular interactions of 
the 3-pyridine substituent at position 9 of the purine ring. 
Accordingly, this moiety not only H-bonds to Tyr202 and 
His259, but also reaches a hydrophobic pocket lined by 
Met221 and Phe161. These experimental results led us to 
Figure 2. Determination of Ki values for a small series of SmPNP inhibitors. Kinetics assays were carried out in the same conditions described in Figure 1. 
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investigate the binding mode of other potent 9-deazaguanine 
inhibitors using different molecular docking strategies. In 
this context, FlexX and GOLD 4.12 were employed to 
cross-dock compound 7 into the SmPNP active site (PDB 
ID 1TD1). The best FlexX solution shows a RMSD of 
1.29Å from the crystallographic coordinates of compound 
7 (Figure 4A). Similar results were obtained with GOLD 
4.12. These initial results prompted us to further explore 
the docking tools to provide additional SAR insights within 
this series.
The binding modes of the 9-deazaguanine derivatives 
shown in Figure 4B highlight the most important 
intermolecular interactions involved in ligand binding. 
The H-bonding pattern between the deazaguanine moiety 
and the side chains of Glu203 and Asn245 is fundamental, 
where the catalytic residue Asn245 donates a hydrogen 
bond to the carbonyl oxygen at the position 6, and accepts 
a hydrogen bond from the N-H group at position 7 of 
the purine ring. Similarly, the residue Glu203 accepts 
hydrogen bonds from the NH2 and NH groups at positions 
2 and 1, respectively. The π-π interaction between the 
electron rich guanine ring and the side chain of Tyr202 
might also be important for inhibitor binding. In addition, 
the side chain of Phe161 from the adjacent subunit 
generates a hydrophobic surface near the site entrance 
(Figure 4), which provides a suitable interaction region 
for hydrophobic moieties at position 9 of the purine ring, 
such as the para-phenyl and para-isopropyl benzyl of 
compounds 19 (IC50 = 0.1 μM) and 18 (IC50 = 0.14 μM), 
respectively. On the other hand, more bulk groups, 
such as the para-cresyl benzyl ether of compound 20 
(IC50 = 0.5 μM), becomes more exposed to solvent and 
led a decrease in potency.
Table 3. Full data collection and refinement statistics for the SmPNP-7 
crystallographic complex
Data collection parameters
Space group P212121
Cell dimensions / Å a = 49.58; b = 132.95; c =121.15
Detector MARMOSAIC 225
X-ray source LNLS MX2
Wavelength / Å 1.43
Resolution range / Å 27.61-2.30 (2.42-2.30)
Redundancy 3.8 (3.9)
Rmeas / (%) 11 (56.7)
Rsym / (%) 9.3 (48.6)
Completeness / (%) 99.8 (100.0)
Total reflections 671970 
Unique reflections 35710 
I/sI 11.4 (3.4)
Refinement parameters
R / (%) 20.4
Rfree / (%) 25.9
Ramachandran plot
Most favoured region / (%) 91.6
Residues in disallowed regions 0.7
Overall B-factor (protein) 36
Mean B-factor (ligand) 61.6
No. protein atoms (one monomer) 6332
No. water molecules 348
No. ligand atoms 76
r.m.s. bond lengths / Å 0.008
r.m.s. bond angles / (deg.) 1.063
Figure 3. Crystallographic structure of compound 7 in complex with SmPNP. A) Electron density (Fo–Fc map), contoured at 3.0δ, where the inhibitor 
was fit. B) Binding profile of compound 7 in the active site of SmPNP. Selected residues from the active site are highlighted in yellow, whereas the protein 
structure is depicted in cartoon. Dashed lines indicate the H-bonding network of compound 7 in the active site of SmPNP.
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Conclusions
The development of new therapeutic approaches to 
combat neglected tropical diseases continues to be one of 
the most important scientific and public health challenges 
facing humankind today. The identification of novel small-
molecule compounds that modulate specific biological 
targets is of great pharmaceutical interest, as this complex 
task requires the use of different drug design technologies.5,30 
The integration of enzyme kinetics, structural analysis and 
molecular modeling studies provided important insights 
into the molecular basis underlying ligand binding affinity 
and SmPNP inhibition. The information gathered in this 
work should be useful in the design of new inhibitors having 
improved potency.
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